Welcome to the Department of Clinical Pharmacy. Our faculty are pioneering new approaches to improving lives through better use of medicines with collaborative health services, precision pharmacotherapy, and translational research. We provide direct patient care through innovative, nationally recognized service models, and are advancing the profession with the next generation of educators and innovators through our PharmD Curriculum, Pharmacy Residency Programs, Clinical Pharmacy Translational Science PhD, and Clinical Pharmacy Translational Science Post-Doctoral Fellowship Program.

Congratulations to Professor Karen Farris for winning the American Pharmacists Association’s Tyler Prize for Stimulation of Research!

The Tyler Prize for Stimulation of Research recognizes an individual(s) for encouraging research by peers, students, fellows, residents, and others via publications or by directing research, serving as a preceptor, or mentoring in any discipline of the pharmaceutical sciences. This award is considered one of the three most prestigious APhA scientific awards and is presented every 3 years.

Dr. Karen Farris recieves the Tyler Prize for Stimulation of Research


Evaluating Risk Prediction Models: From Practice to Policy

Speaker Photo

Dr. Karandeep Singh will be presenting on 10/09/2023 from 12-1:30pm in room 1544 NUB. A zoom link can be found on the following flier, we hope to see you there!

Karandeep Singh, MD, MMSc, is an Assistant Professor of Learning Health Sciences, Internal Medicine, Urology, and Information at the University of Michigan. He directs the Machine Learning for Learning Health Systems (ML4LHS) Lab, which focuses on translational issues related to the implementation of machine learning models within health systems. He serves as an Associate Chief Medical Information Officer of Artificial Intelligence for Michigan Medicine and is the Associate Director for Implementation for Precision Health at the University of Michigan. He teaches a health data science course for graduate and doctoral students, and provides clinical care for people with kidney disease.

He completed his internal medicine residency at UCLA Medical Center, where he served as chief resident, and a nephrology fellowship in the combined Brigham and Women’s Hospital/Massachusetts General Hospital program in Boston, MA. He completed his medical education at the University of Michigan Medical School and holds a master’s degree in medical sciences in Biomedical Informatics from Harvard Medical School. He is board certified in internal medicine, nephrology, and clinical informatics.

His work in machine learning and digital health has been published in leading journals in their respective fields, including the New England Journal of Medicine, Lancet, British Medical Journal, JAMA Internal Medicine, Nature Machine Intelligence, Health Affairs, Clinical Journal of the American Society of Nephrology, Ophthalmology, Radiology, and European Urology.

Faculty Spotlight

David Frame Photo

David Frame is a Cell therapy and Immuno-Hematology pharmacy specialist at Michigan Medicine and Clinical Assistant Professor at University of Michigan College of Pharmacy. Dr. Frame earned his Bachelor of Science in Chemistry from St Louis University as well as BS in Pharmacy and PharmD from Wayne State University. He completed an Oncology residency at the University of Illinois in Chicago and then practiced as an oncology, hematology and stem cell transplant specialist at Rush Medical Center in Chicago. While at Rush he also held a faculty appointment in Pharmacology in the Medical school. He developed several clinical services while there including anticoagulation, palliative care, rheumatology and was director of oncology pharmacy research. Dr. Frame joined the University of Michigan in 2005.

At Michigan Medicine Dr. Frame currently is active in caring for and optimizing therapy for stem cell transplant and Chimeric Antigen Receptor T cell therapy patients where he has active research in developing therapies to both minimize toxicity and maximize response. A new line of research is in the development of a potentially new mechanism to treat certain types of graft versus host disease (GVHD), an often debilitating condition effecting both morbidity and mortality after allogeneic transplant. Dr. Frame describes one of his most challenging endeavors is in helping to define therapies for Immuno-Hematology patients, who generally have very rare immunologic disorders that have limited or no therapies available. He is also working with a biomedical engineering group at Michigan to help develop clinical uses for personalized medicine tool that was developed that can measure real time cytokine levels and is helping to adapt it to measure other important assays that are difficult to obtain, including certain types of drug levels. He is currently utilizing this approach to help develop more timely and appropriate therapies for children with Inflammatory Bowel Disorders and is developing protocols for evaluating the use in GVHD, in monitoring immune changes with Tacrolimus, in predicting graft failure with stem cell transplant, and for helping to treat multiple other inflammatory conditions such as hemophagocytic lymphohistiocytosis and macrophage activation syndrome.

Dr. Frame has been active in many organizations including the Hematology Oncology Pharmacy Association where he had served as chair of the research committee, the International Supportive Care in Oncology Pharmacy Practice. He was the scientific chair of the International Foundation for CDKL5 Research for several years and is currently working on developing a pharmacy section of the newly developed North American Immuno-Hematology Education and Research (NICER) consortium.

Dr. Frame has taught in the Michigan College of Pharmacy immunology and oncology therapeutics sections for several years and has had over 200 students and residents on rotation. He has a firm commitment to challenge students to not just learn but to apply their knowledge and to utilize their knowledge from multiple disciplines at one time. As a result, he has helped to develop the pharmacology program and to integrate more clinical aspects of pharmaceutical sciences.

Some of his research publications include:

  • Frame D, Scappaticci GB, Braun TM, et al. Defibrotide Therapy for SARS-CoV-2 ARDS. Chest. 2022 :S0012-3692(22)00593-1. doi: 10.1016/j.chest.2022.03.046
  • Weyand AC, Barbaro RP, Walkovich KJ, Frame DG. Adjustments to pharmacologic therapies for hemophagocytic lymphohistiocytosis while on extracorporeal support. Pediatr Blood Cancer. 2021;68(6):e29007. doi: 10.1002/pbc.29007.
  • Song Y, Ye Y, Su SH, et al. A digital protein microarray for COVID-19 cytokine storm monitoring. Lab Chip. 2021;21(2):331-343. doi: 10.1039/d0lc00678e
  • Chang L, Frame D, Braun T, et al. Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes. Biol Blood Marrow Transplant. 2014;20(9):1407-17. doi: 10.1016/j.bbmt.2014.05.022.